Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Raymond James Financial

Raymond James Financial upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) to a strong-buy rating in a research note issued to investors on Thursday,Zacks.com reports.

A number of other equities research analysts also recently weighed in on ASND. JPMorgan Chase & Co. upped their price target on shares of Ascendis Pharma A/S from $260.00 to $264.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Cowen reiterated a “buy” rating on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Cantor Fitzgerald increased their target price on shares of Ascendis Pharma A/S from $203.00 to $254.00 and gave the company an “overweight” rating in a research note on Monday, October 13th. Bank of America raised their target price on shares of Ascendis Pharma A/S from $227.00 to $230.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Finally, Morgan Stanley initiated coverage on Ascendis Pharma A/S in a report on Thursday, July 3rd. They issued an “overweight” rating and a $250.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $249.80.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $210.50 on Thursday. The stock has a fifty day moving average price of $199.16 and a two-hundred day moving average price of $177.64. The firm has a market cap of $12.99 billion, a P/E ratio of -40.79 and a beta of 0.41. Ascendis Pharma A/S has a 1 year low of $118.03 and a 1 year high of $216.45.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.49. The firm had revenue of $216.28 million during the quarter, compared to the consensus estimate of $163.17 million. On average, research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of large investors have recently made changes to their positions in the company. Compagnie Lombard Odier SCmA acquired a new position in Ascendis Pharma A/S in the 2nd quarter worth approximately $39,000. First Horizon Advisors Inc. purchased a new stake in shares of Ascendis Pharma A/S in the second quarter valued at $41,000. Brooklyn Investment Group boosted its position in shares of Ascendis Pharma A/S by 332.9% in the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company’s stock worth $55,000 after buying an additional 273 shares during the period. Hantz Financial Services Inc. boosted its position in shares of Ascendis Pharma A/S by 291.1% in the second quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock worth $61,000 after buying an additional 262 shares during the period. Finally, Farther Finance Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 115.3% during the third quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock valued at $95,000 after buying an additional 256 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.